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A growing body of evidence has delineated the predominant role of humoral mediators of inﬂammation
in linking sleep with immunity. Nonetheless, characterization of the relationship between complement
components with inﬂammatory functions and objective sleep measures has not been performed. In this
study we investigated the relationships between objective measures of sleep and complement compo-
nents with inﬂammatory functions. Thirty-six healthy male university students (age, 23.9474.23 years;
BMI, 23.4472.67 kg/m2) completed the study. An RMS Quest 32 polysomnograph (PSG) was used for
sleep recording. Non-fasting blood was collected before subjects went to bed on the second night in the
sleep laboratory to estimate complement component 3 (C-3), complement component 4 (C-4), com-
plement factor-H (Factor-H), C1-inhibitor (C1INH), complement factor I (CFI) and other inﬂammatory
mediators, such as IL-6 and sICAM-1. Multiple linear regression analysis was used to assess the asso-
ciation between PSG sleep measures and inﬂammatory mediators. Higher values of C-3 and lower values
of sICAM-1, C1INH, and CFI (adjusted model, R2¼0.211, po0.041) predicted longer sleep duration. Lower
C-3 (adjusted model, R2¼0.078, po0.055) predicted higher N1 (%). Higher levels of C1INH and CFI and
lower values of C-4 (model adjusted R2¼0.269, po0.008) predicted higher N3 (%). Higher C-3, higher
C-4, lower IL-6, lower C1INH and lower CFI (model adjusted R2¼0.296, po0.007) predicted higher REM
(%). Poor sleep measures were associated with increased levels of pro-inﬂammatory complement com-
ponents and decreased anti-inﬂammatory complement components.
& 2016 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Complement is a complex innate immune surveillance system
that plays a pivotal role in defense against pathogens and in host
homeostasis [1,2]. This complement system assists antibodies and
phagocytes in removing pathogens from the organism. The systemduction and Hosting by Elsevier B.
ment of Biomedical Sciences,
zan Campus), Ethiopia.
),
mail.com (W. Zannat),
iation of Sleep.is composed of approximately 30 molecules, some of which play
an important role in the inﬂammation mechanism [3,4]. Comple-
ment components mediate inﬂammation upon activation as a
consequence of the imbalance in the crosstalk between various
serum mediators of this protective mechanism [5,6]. The intricate
balance among the inﬂammatory mediators in the serum is dis-
rupted during sleep problems [7].
Slow wave sleep (SWS) has several important functions, which
include roles in cerebral restoration and recuperation in humans
[8,9]. Moreover, SWS contributes to the recovery process, up-reg-
ulation of the production of pro-inﬂammatory cytokines, genera-
tion of a pro-inﬂammatory hormonal milieu and suppression of
anti-inﬂammatory hormones [10]. A growing body of data has
demonstrated a link between sleep and inﬂammatory mediators
[6,7,12]. Few studies have explored the serum pattern of comple-
ment components from the perspective of sleep with varyingV. This is an open access article under the CC BY-NC-ND license
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the use of heterogeneous sleep loss protocols and screening for
limited numbers of complement components [13–15]. We have
recently reported the relationship between subjective sleep qual-
ity measures and inﬂammatory complement components [16].
However, the generalizability of those ﬁndings to normal objective
polysomnographic (PSG) measures of sleep is difﬁcult to appraise
[6,13,14,16]. Furthermore, for a better assessment of the associa-
tion between sleep and inﬂammatory mediators, objective mea-
surement of sleep parameters is recommended [17].
We hypothesized that the higher level of pro-inﬂammatory
complement components and/or lower level of anti-inﬂammatory
complement components predict poor PSG sleep measures.
Therefore, we conducted this study to assess the association be-
tween the serum levels of the complement components and PSG
sleep measures. Additionally, the serum levels of IL-6 and sICAM-1
were estimated, to aid in the one-point comparative assessment of
the associative dynamics of the inﬂammatory complements vis-à-
vis other classes of inﬂammatory molecules.2. Materials and methods
2.1. Ethical clearance, participants, and study design
In this cross-sectional, observational study, volunteers were
selected after clinical interview for exclusion and inclusion criteria.
The advertisement for volunteers was put on university website,
and notice boards of the departments, centers, faculty and hostel
ofﬁces of the varsity. Inclusion criteria included healthy male
university students. None of the participants reported treatment
for non-communicable chronic conditions, e.g., sleep disorders,
neurologic disorders, diabetes, cardiovascular diseases, and psy-
chological/psychiatric (depression, stress) illnesses. None of the
participants reported major injury, chronic pain conditions, sur-
gery or use of narcotics. The participant characteristics are given in
Table 1. The study sample consisted of 36 unmarried, male, uni-
versity students. The volunteers were enrolled in various under-
graduate (n¼16) and postgraduate (n¼20) courses at the uni-
versity. The sample comprised young (age¼23.9474.23 yr) uni-
versity students of north Indian and south Indian (Malayali)
ethnicities.
A complete explanation regarding the purpose and procedures
of the study was given to the participants. Written informed
consent was obtained from all participants prior to enrollment, in
compliance with the institutional ethics guidelines and theTable 1
Participant's characteristics.
Characteristics Mean7SD/frequency
Age (yr) 23.9474.23
Height (cm) 167.2274.27
Weight (kg) 65.5077.38
BMI (kg/m2) 23.4472.67
Under-weights 01
Normal 25
Over-weight 10
Ethnicity
South Indian (Malayalee) 20
North Indian 16
Courses
Under-graduate 16
Post-graduate 20
Alcohol consumer 01
Smokers 04
BMI: body mass index.Helsinki Declaration. The study was approved by the Human In-
stitutional Ethics Committee, Jamia Millia Islamia, New Delhi,
India.2.2. Sleep evaluation: PSG
The overnight PSG sleep recording was performed with an RMS
Quest 32 polysomnograph (Recorders and Medicare Systems,
Chandigarh, India). The participants underwent two PSGs. The ﬁrst
night served as an adaptation night to the sleep laboratory con-
ditions (data from this night were not included in the analysis).
The PSG records were scored in accordance with the AASM man-
ual, 2007 [18] by a well-trained experienced sleep scorer. The
standard recommendations for EEG (three derivations; F4-M1, C4-
M1 and O2-M1), EOG (two derivations; E1-M1 and E2-M2), chin
EMG, ECG (two electrode), limb movement (piezocrystal elec-
trode), and blood oxygen saturation level (SPO2) were employed.2.3. Blood extraction, serum separation, storage and ELISA
Blood was taken from the anti-cubital vein 1–2 h before the
subjects’ bedtime on the second night in the sleep laboratory.
Blood was kept undisturbed at room temperature for 30 min for
clotting and was then centrifuged at 5000 rpm for 5 min at 4 °C for
serum separation. The isolated serum samples were kept frozen at
80 °C prior to quantiﬁcation. The protocol was in consideration
of the published reports of the secondary structure stability,
complement integrity and bactericidal activity maintenance
[19,20].
Serum C-3, C-4, sICAM-1, C1 inhibitor (C1INH), complement
factor-H (Factor-H), complement factor I (CFI) and IL-6 were as-
sayed using commercially available ELISA kits: sICAM-1 and IL-6
(Thermo Fisher Scientiﬁc Inc., Rockford, USA); Factor-H, C-4 and
C-3 (Abcam, Cambridge, UK); CFI and C1INH (Santa Cruz Bio-
technology, Inc. New Bond St Bath, UK). The ELISA testing was
performed according to the manufacturers’ protocols.2.4. Statistical analysis
Descriptive statistics were used to assess the mean7standard
deviation of the normally distributed parametric variables, and the
median7 inter-quartile range was used for non-normally dis-
tributed parametric data and/or non-parametric variables. Multi-
ple linear regression analysis was used to assess the relationship
between sleep and inﬂammatory mediators. Analysis was per-
formed separately for each of the selected PSG sleep measures
with a joint multivariate outcome deﬁned by all seven in-
ﬂammatory mediators. Inclusion of variables was dependent on
earlier reports and theoretical considerations. Nine PSG sleep
measures, i.e., TST (min), sleep onset latency (SOL), REMOL, WASO,
awake time (%), N1 (%), N2 (%), N3 (%) and REM (%), were chosen
for assessment of the association with inﬂammatory mediators.
These measures represent different domains of sleep, and prior
studies have indicated a possibility of their association with in-
ﬂammatory mediators [6,12,21]. Two-sided tests were used for all
statistics, and the level of signiﬁcance was set at po0.05. Some
results with po0.01 are also reported to show the trends. Vari-
ables with non-Gaussian distributions were transformed to loga-
rithmic and square root derivations for regression analysis. SPSS
16.0 (SPSS Inc., Chicago, Illinois) was used for the statistical
analysis.
Table 2
Sleep measures and inﬂammatory mediators.
Sleep measures/Inﬂammatory mediators Mean7SD/Median (IQR)
TST (min) 374.02765.98
SOL (min) 8.50 (7.38)a
SE (%) 93.5973.55
REMOL (min) 92.00 (90.38)a
WASO (min) 6.25 (20.38)a
Awake time (%) 5.17 (6.10)a
N1 (%) 6.00 (6.21)a
N2 (%) 43.3678.25
N3 (%) 26.3879.77
REM (%) 17.1675.21
ODI 4.3372.93
Mean SpO2 95.9070.83
C3 (μg/ml) 1442.007109.48
C4 (μg/ml) 453.58744.21
Factor-H (μg/ml) 515.287127.84
C1INH (μg/ml) 193.14727.37
CFI (μg/ml) 64.5575.37
IL-6 (pg/ml) 1.3270.09
sICAM-1 (μg/ml) 0.1970.03
TST: Total sleep time, SOL: sleep onset latency, SE: sleep efﬁciency, REMOL: REM
onset latency, WASO: Duration of wake after sleep onset, NREM: Non-rapid eye
movement sleep, N1: sleep stage N1, N2: sleep stage N2 and N3: sleep stage N3,
REM: Rapid eye movement sleep, ODI: oxygen desaturation index, Mean SpO2:
mean oxygen saturation.
C3: Complement Component-3, C4: Complement Component-4, Factor-H: Com-
plement Factor-H, C1INH: C1-inhibitor, CFI: Complement Factor I and IL-6: Inter-
leukin-6, sICAM-1: soluble Intercellular Adhesion Molecule-1.
a Median (IQR).
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3.1. Sleep measures and inﬂammatory mediators
The descriptive statistics of the PSG sleep measures and in-
ﬂammatory mediators are shown in Table 2. Six of the sleep
measures, i.e., SOL, REMOL, WASO, awake time (%), and N1 (%),
were not normally distributed; therefore, their values are shown
as the median (inter-quartile range) (Table 2). The PSG showed
that the participants had no sleep disorders. The serum levels of all
measured inﬂammatory mediators were within the normal range.
3.2. Association between sleep measures and IIPs
Multiple linear regression analyses were performed in-
dividually for each PSG sleep measure to determine the extent to
which the inﬂammatory mediators predict changes in sleep
parameters. BMI and BMI2 were entered in one block along with
the 7 inﬂammatory mediators as independent variables, and the
backward method was used. The multiple regression analysisTable 3
Multiple regression predictors of polysomnographic sleep measures.
Sleep variable Signiﬁcant individual predictor variables (ß coefﬁcients; P values)
TST C-3 (0.941, 0.001); sICAM-1 (0.337, 0.069); C1INH (0.733, 0.002);
0.066), BMI2 (4.709, 0.080)
REMOLa C-3 (0.351, 0.020); BMI (0.494, 0.002)
N1 (%)a C-3 (0.323, 0.055)
N2 (%) sICAM-1 (0.275, 0.076), Factor-H (0.565, 0.003); C1INH (0.383, 0.0
N3 (%) C-4 (0.653, 0.015); C1INH (0.487, 0.010); CFI (0.357, 0.031); BMI2 (
REM (%) C-3 (0.482, 0.041); C-4 (0.588, 0.046); IL-6 (0.463, 0.014); C1INH (
TST: total sleep time, REMOL: REM onset latency, WASO: duration of wake after sleep ons
stages 1, 2 and of NREM, REM: rapid eye movement sleep.
C-3: Complement Component 3, C-4: Complement Component 4, sICAM-1: Intercellul
Complement factor I.
a Logarithmic transformed for making distribution normal.results of 6 of the 9 PSG sleep measures are presented in Table 3.
SOL, WASO, and awake time (%) were not associated with in-
ﬂammatory mediators. REMOL and N1 (%) were log-transformed
to satisfy the normality distribution requirement of the regression
analysis.
Longer TST was predicted by higher C-3, lower sICAM-1, lower
C1INH, lower CFI, higher BMI and lower BMI2 (model adjusted
R2¼0.211, po0.041). Longer REMOL was predicted by lower ser-
um C-3 level and higher BMI (model adjusted R2¼0.291,
po0.001). Higher N1 (%) was predicted by lower C-3(model ad-
justed R2¼0.078, po0.055). Greater N2 (%) was predicted by a
lower serum level of sICAM-1, lower C1INH, higher serum Factor-H
and higher BMI (model adjusted R2¼0.308, po0.004). Greater N3
(%) was predicted by a higher serum level of C1INH and CFI, lower
BMI2 and lower serum C-4 (model adjusted R2¼0.269, po0.008).
A higher REM % was predicted by higher C-3, higher C-4, lower IL-
6, lower C1INH and lower CFI (model adjusted R2¼0.296,
po0.007).4. Discussion
The results support our hypothesis that the pro/anti-in-
ﬂammatory complement components can predict PSG sleep
measures. The associations between objective sleep measures and
inﬂammatory complement components are similar to those be-
tween objective sleep measures and inﬂammatory cytokines. The
majority of the selected PSG sleep measures (66.67%) were pre-
dicted by inﬂammatory complement components and other in-
ﬂammatory mediators. These results reafﬁrm the conclusions of
previous studies of the existence of an association between ob-
jective sleep measures and inﬂammatory mediators [21–24]. Our
results concur with a previous study in healthy individuals that
has shown that the inﬂammatory molecules IL-6 and sICAM-1 are
not associated with SOL [21]. Our results extended this study,
showing that inﬂammatory cytokine IL-6, inﬂammatory cell ad-
hesion molecule sICAM-1 and inﬂammatory complement com-
ponents were not associated with SOL (Table 3). Lower sleep
duration (TST) was associated with higher sICAM-1, C1INH, CFI and
lower C-3. C-3 and sICAM-1 have pro-inﬂammatory functions
[25,26]. C1INH, Factor-H and CFI are anti-inﬂammatory in nature
[3,27]. Lower sleep duration is associated with increased serum
inﬂammatory marker TNF-α [23]. Patel et al. have found that re-
duced PSG sleep duration is associated with increased levels of
pro-inﬂammatory cytokine TNF-α. The authors concluded that
extremes of sleep duration are associated with inﬂammation [23].
Moreover, similarly to earlier reports [28–30], in this male-ex-
clusive study, no association between sleep duration and IL-6 was
found. In contrast to earlier reports, we did not ﬁnd an associationModel unadjusted R2; adjusted R2; P value
CFI (0.638, 0.011); BMI (4.997, 0.346, 0.211, 0.041
0.332, 0.291, 0.001
0.104, 0.078, 0.055
33); BMI (0.573, 0.001) 0.387, 0.308, 0.004
0.453, 0.009) 0.353, 0.269, 0.008
0.409, 0.054); CFI (0.797, 0.004) 0.397, 0.296, 0.007
et, NREM: non-rapid eye movement sleep, NREM1, NREM2, NREM3: represent sub-
ar Adhesion Molecule 1, Factor-H: complement factor-H, C1INH: C1-inhibitor, CFI:
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vious studies included hypertensive individuals, which may have
confounded the results because hypertension is associated with IL-
6 [31]. Similarly to earlier reports, our study did not ﬁnd an as-
sociation between N1 (%) and IL-6 [21,22]. However, N1 (%) was
negatively associated with anti-inﬂammatory complement com-
ponent Factor-H (Table 3).
Both C-3 and C-4 were signiﬁcantly associated with REM sleep
(Table 3). This result is striking, given that there is commonality
between the rhythm pattern of C-3, C-4, and REM sleep regulation.
REM sleep has a predominant circadian regulation [32], and the
serum levels of both C-3 and C-4 have well-characterized circadian
patterns [14], which gives further insight into the possible phy-
siological basis of our experimental hypothesis, i.e., the similarity
between the association pattern of sleep and inﬂammatory cyto-
kines and the association pattern of sleep and inﬂammatory
complement components. The circadian aspect of sleep maintains
stable and healthy cytokine rhythms [33] and may play a role in
the maintenance of stable and healthy complement component
rhythms. SWS was positively associated with anti-inﬂammatory
serum complements (C1INH and CFI) and was negatively asso-
ciated with pro-inﬂammatory serum C-4 (Table 3), which is in
agreement with the theme that poor sleep is associated with in-
creased pro-inﬂammatory markers and suppressed anti-in-
ﬂammatory serum cytokine levels [34].
Awake time comprises SOL and WASO and is a negative in-
dicator of sleep quality. In contrast to the report of Taheri et al.,
2004, a negative curvilinear relationship between TST and BMI
was found (Table 3), which might be due to differences between
the samples of the two studies, such as age (almost 3 decades),
BMI (approximately 6 kg/m2), gender composition, and the pre-
sence of chronic diseases, e.g., diabetes and hypertension [24].
The relationship between sleep and inﬂammatory cytokines is
affected by gender [11,35]. Likewise, disease linked differences in
sleep and inﬂammatory cytokines relationship have been pre-
viously documented [11]. The ﬁndings of this study provide pri-
mary evidence of polysomnographic correlates of inﬂammatory
complement components in healthy young males. Future studies
should explore the dynamics of this association between objective
sleep measures and inﬂammatory complement components
among females and across different age groups and co-
morbidities.
The limitations of our study include a relatively small sample
size and that serum samplings for inﬂammatory complement
components and other inﬂammatory mediators were performed
at one time point (before subjects went to bed). The serum levels
of inﬂammatory molecules, e.g., IL-6, C-3, and C-4, exhibit distinct
circadian patterns in healthy individuals [14,36]. The blood sam-
pling was done during a close range of time to avoid the effect of
the circadian variability on the serum levels of the measured in-
ﬂammatory molecules. Therefore, observation of the serum levels
of inﬂammatory molecules at multiple time points may provide
pertinent information about the circadian rhythm-dependent dy-
namics of their relation to sleep. However, the use of catheters for
repeated blood sampling increases IL-6 locally [37]. Therefore,
future studies should account for this fact to provide a compre-
hensive understanding of the association. Nevertheless, this is the
ﬁrst study to report that the inﬂammatory mediators across three
classes of immune-regulatory molecules of cytokines, cell adhe-
sion molecules, and complement components are similar in their
associational dynamics with sleep. This study is a preliminary
study to investigate the relationship between objective measures
of sleep and inﬂammatory complement components. The normal
level of oxygen desaturation index (4.3372.93) and mean SpO2
(95.9070.83) indicated absence of apnea in the participants [38].
The ﬁndings of this study suggest a need for sleep evaluation inhealth conditions where complement components are affected.
Future studies should investigate sleep under conditions of com-
plement component deﬁciencies and increased production (acute/
chronic and local/systemic). More research is necessary to under-
stand the obverse facet, i.e., the serum levels of complement
component in sleep disorders. The application of anti-in-
ﬂammatory medicines that affect the production and/or serum
availability of inﬂammatory complement components (C-3, C-4,
Factor-H, CFI, and C1INH) and/or inﬂammatory mediators (IL-6,
sICAM-1) for the prospective management of sleep in patients
suffering from chronic and/or systemic inﬂammation should be
investigated.5. Conclusion
Poor sleep measures in general were associated with heigh-
tened serum pro-inﬂammatory complement components and de-
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